OncoMatch

OncoMatch/Clinical Trials/NCT06431685

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Is NCT06431685 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Pemetrexed and Sintilimab for nsclc.

Phase 1RecruitingSichuan UniversityNCT06431685Data as of Jun 2026Location: China

Treatment: Pemetrexed · Sintilimab · ChemotherapyThis phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Sintilimab

Chemotherapy

Pemetrexed

Other

Chemotherapy

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–3(Limited self-care)

Demographics

Ages ≤ 75

Lab requirements

Blood counts

Hemoglobin ≥80 g/L, neutrophils ≥1.5×10^9/L and platelets ≥70×10^9/L

Kidney function

Cr≤ULN × 1.5, endogenous creatinine clearance (Ccr)≥55 ml/min

Liver function

total bilirubin ≤ULN × 1.5; ALT, AST≤ULN × 2.5; (In case of liver metastasis, total bilirubin should not be higher than 3 times the upper normal limit, and transaminase should not be higher than 5 times the upper normal limit)

bone marrow and liver and kidney function met the following criteria: Hemoglobin ≥80 g/L, neutrophils ≥1.5×10^9/L and platelets ≥70×10^9/L; Cr≤ULN × 1.5, endogenous creatinine clearance (Ccr)≥55 ml/min; total bilirubin ≤ULN × 1.5; ALT, AST≤ULN × 2.5; (In case of liver metastasis, total bilirubin should not be higher than 3 times the upper normal limit, and transaminase should not be higher than 5 times the upper normal limit)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06431685 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify